NewGenIvf Group (NIVF) files Form 6-K with H1 2025 unaudited results

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

NewGenIvf Group Limited filed a Form 6-K as a foreign private issuer to furnish its unaudited financial results for the six months ended June 30, 2025. These interim results are provided as an exhibit to the report rather than being fully detailed in the body of the filing.

The company notes that the financial information is unaudited and may be adjusted when year-end audit procedures are performed, which could lead to significant differences from the numbers currently presented in the interim results.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 10/09/2025 - 07:42 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-42004

NEWGENIVF GROUP LIMITED

36/39-36/40, 13th Floor, PS Tower

Sukhumvit 21 Road (Asoke)

Khlong Toei Nuea Sub-district

Watthana District, Bangkok 10110

Thailand

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Interim Results for the Six Months Ended June 30, 2025

The unaudited financial results for the six months ended June 30, 2025 (“Interim Results”) of NewGenIvf Group Limited (“NewGen”) and its subsidiaries (collectively, the “Company”) is furnished as Exhibit 99.1 to this report on Form 6-K.

Statement Regarding Unaudited Financial Information

The unaudited financial information set out in this earnings release is subject to potential adjustments. Adjustments to the consolidated financial statements may be identified when audit work is performed for the Company’s year-end audit, which could result in significant differences from this unaudited financial information.

EXHBIT INDEX

Exhibit No.		Description
99.1		NewGenIvf Group Limited’s Unaudited Financial Results for the Six Months Ended June 30, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 9, 2025

	NewGenIvf Group Limited

	By:	/s/ Wing Fung Alfred Siu
	Name:	Wing Fung Alfred Siu
	Title:	Chairman of the Board and Director

Source: View Original Filing on SEC EDGAR

FAQ

What did NewGenIvf Group Limited (NIVF) file on Form 6-K?

NewGenIvf Group Limited furnished a Form 6-K as a foreign private issuer to provide its unaudited financial results for the six months ended June 30, 2025, as an exhibit.

Which period do NewGenIvf Group Limited’s interim results on this 6-K cover?

The interim results cover the six-month period ended June 30, 2025, and are attached to the Form 6-K as Exhibit 99.1.

Are NewGenIvf Group Limited’s interim financial results on this 6-K audited?

No. The company states that the financial information is unaudited and may be subject to adjustments identified during the year-end audit, which could result in significant differences.

How are NewGenIvf Group Limited’s interim results presented in the Form 6-K?

The interim results are furnished as Exhibit 99.1 titled “NewGenIvf Group Limited’s Unaudited Financial Results for the Six Months Ended June 30, 2025.”

What is the purpose of NewGenIvf Group Limited using Form 6-K?

As a foreign private issuer, NewGenIvf Group Limited uses Form 6-K to furnish information such as interim financial results to the U.S. market under the Securities Exchange Act of 1934.

Who signed NewGenIvf Group Limited’s Form 6-K for the June 30, 2025 interim results?

The Form 6-K was signed on behalf of NewGenIvf Group Limited by Wing Fung Alfred Siu, who is identified as Chairman of the Board and Director.